您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 英国药房
产地国家: 英国
所属类别: 抗微生物药物->抗炎
处方药:处方药
包装规格: (100/20)毫克/胶囊 30胶囊/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
Meda
生产厂家英文名:
Meda
该药品相关信息网址1:
http://www.axorid.com/professionals/what-is-axorid.php
原产地英文商品名:
AXORID MR CAP (100/20)mg/cap 30caps/bottle
原产地英文药品名:
KETOPROFEN/OMEPRAZOLE
中文参考商品译名:
AXORID MR胶囊 (100/20)毫克/胶囊 30胶囊/瓶
中文参考药品译名:
酮洛芬/奥美拉唑
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Osteoarthritis
英文适应病症2:
Rheumatoid arthritis
英文适应病症3:
Ankylosing Spondylitis
英文适应病症4:
Prevention of gastric ulcers and bleeding
临床试验期:
完成
中文适应病症参考翻译1:
骨关节炎
中文适应病症参考翻译2:
风湿性关节炎
中文适应病症参考翻译3:
强直性脊柱炎
中文适应病症参考翻译4:
预防胃溃疡及出血
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(2010101100055927.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Axorid XR处方资料(仅供参考)

    由酮洛芬和奥美拉唑组成得第一种复方制剂——Axorid,在缓解骨关节炎、风湿性关节炎和强直性脊柱炎等疾病的疼痛时,还能有效预防胃溃疡及出血,双重保护患者生命健康。

    日前,英国研究人员发现,一种新型非甾体类抗炎药Axorid,在缓解疼痛的同时还能防止胃溃疡及出血,给患者带来双重功效。

    这种药物名为Axorid的新药,瑞典Meda制药公司研制的新型复方制剂,主要由酮洛芬和奥美拉唑组成。Axorid已于今年年初,在英国获准用于治疗骨关节炎、风湿性关节炎和强直性脊柱炎。

    胃出血是非甾体类抗炎药(NSAID)最常见的不良反应之一。每年因服用NSAID而导致肠胃出血的患者达4000例左右,其中700人死亡。

    爱丁堡大学肝脏病学教授及皇家医院荣誉顾问医师皮特•海耶斯表示,将NSADI和PPI同时使用是减少用药副作用和保护胃部的惯用方法,但患者经常忘记或不愿意同时使用两种药物,因此将这两种成分基于一体可以增强患者对药物的依从度,也是一种实用有效的方法。

    Axorid的正式上市,将为那些需要长期服用NSAID的患者提供一种性能更全面的“武器”,既能发挥非甾体类抗炎药的治病功效,又能有效防治其不良反应。

Drug Name:  ketoprofen / omeprazole (Axorid)

SMC Drug ID:  606/10

Manufacturer: Meda Pharmaceuticals Ltd

Indication: For symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients who have a history or are at risk of developing non-steroidal anti-inflammatory drug-associated gastric ulcers, duodenal ulcers and gastroduodenal erosions, and in whom continued treatment with ketoprofen is essential. 

BNF Category: 10. Musculoskeletal and joint diseases 

Sub Category: 10.1 Drugs used in rheumatic diseases and gout

Axorid® is a combination of the non-steroidal anti-inflammatory drug (NSAID) ketoprofen and the proton pump inhibitor (PPI) omeprazole.

Axorid® is the only medicine that combines an NSAID and a PPI, the gastroprotector of choice for preventing NSAID-induced gastrointestinal side-effects.

Likewise, Axorid® is the only medicine to combine an NSAID and a gastroprotective agent in a single capsule for once-daily administration.

Axorid® is indicated for the symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a previous history or who are at risk of developing NSAID associated gastric ulcers, duodenal ulcers and gastroduodenal erosions in whom continued treatment with ketoprofen is essential.

For further information on Axorid® please see full prescribing information

Why does Axorid® contain omeprazole?
PPIs are recommended by rheumatology guidelines as the gastroprotective agents of choice in patients taking NSAIDs 1-4.

PPIs prevent the development of gastric and duodenal ulcers, as well as serious ulcer complications in patients taking NSAIDs 5-16.

Unlike misoprostol, PPIs also relieve dyspeptic symptoms in NSAID users, present good gastrointestinal tolerability, and are effective when administered in a once-daily dose 8,13,16-22.

Why does Axorid® contain ketoprofen?
Ketoprofen is a potent anti-inflammatory and analgesic medication 23-27 able to effectively improve a variety of symptoms of rheumatic diseases such as pain, inflammation, morning stiffness and tenderness, leading to an improvement in joint mobility 23,27.

Ketoprofen has demonstrated efficacy and safety both in the short- and long-term 23,27.

Why is Axorid® available as once-daily sustained-release capsules?
A single daily dose is considered an optimal NSAID regimen for the management of chronic diseases such as osteoarthropathy 28. This is because the simplicity of once-daily dosing favours a correct adherence to treatment. In osteoarthritis patients, it has been reported that NSAIDs administrated once daily yield compliance rates of over 95% 29.

Sustained-release (SR) forms have the potential to reduce NSAID side effects, compared to conventional oral forms, as sudden plasma peaks are reduced, and high local drug concentrations in the gastrointestinal tract are avoided. In line with this, ketoprofen SR has been shown to be associated with better tolerability than conventional ketoprofen 30.

Sustained-release (SR) forms may lead to optimised efficacy profiles as they produce less fluctuating plasma levels, and this may lead to more consistent therapeutic effects 31. Once-daily ketoprofen SR is associated with significantly greater efficacy than conventional ketoprofen immediate-release (IR) for a number of variables (pain assessment in osteoarthritis of the knee and the hip, global evaluation and improvement of movements in osteoarthritis of the hip, and walking distance in rheumatoid arthritis) 32. 
 

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(2010101100055927.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2014-09-04
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com